Prospective observational study of Fremanezumab (Ajovy™) effectiveness in chronic and episodic migraine patients in clinical routine: FINESSE study

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/48417
• EU PAS number:
  EUPAS44606
• Study ID:
  48417
• Official title and acronym:
  Prospective observational study of Fremanezumab (Ajovy™) effectiveness in chronic and episodic migraine patients in clinical routine: FINESSE study
• DARWIN EU® study:
  No
• Study countries:
  Austria

  Germany
• Study status:
  Ongoing

Research institutions and networks

Institutions

Ludwig-Maximilians-University Munich

Study timelines

Date when funding contract was signed

Actual: 03/09/2019

Study start date

Planned: 18/11/2019

Actual: 18/11/2019

Date of final study report

Planned: 31/12/2024

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Teva GmbH

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

Paul-Ehrlich-Institut (PEI) NIS-number 506